ANTI-HETEROGENEOUS NUCLEAR RIBONUCLEOPROTEIN B1 (ANTI-RA33) ANTIBODIES IN RHEUMATOID ARTHRITIS AND SYSTEMIC SCLEROSIS

Anti-heterogeneous nuclear ribonucleoprotein (RNP) autoantibodies (AAbs) are encountered in many autoimmune rheumatic diseases (ARDs). The potential diagnostic value of the RA33 AAb complex consisting of RNP A2 and alternative domains of the splicing proteins RNP B1 and RNP B2 is now of interest to...

Full description

Saved in:
Bibliographic Details
Main Authors: P. A. Kuznetsova, A. L. Maslyansky, S. V. Lapin, O. Yu. Tkachenko, V. I. Mazurov
Format: Article
Language:Russian
Published: IMA PRESS LLC 2017-04-01
Series:Научно-практическая ревматология
Subjects:
Online Access:https://rsp.mediar-press.net/rsp/article/view/2357
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1839568371198197760
author P. A. Kuznetsova
A. L. Maslyansky
S. V. Lapin
O. Yu. Tkachenko
V. I. Mazurov
author_facet P. A. Kuznetsova
A. L. Maslyansky
S. V. Lapin
O. Yu. Tkachenko
V. I. Mazurov
author_sort P. A. Kuznetsova
collection DOAJ
description Anti-heterogeneous nuclear ribonucleoprotein (RNP) autoantibodies (AAbs) are encountered in many autoimmune rheumatic diseases (ARDs). The potential diagnostic value of the RA33 AAb complex consisting of RNP A2 and alternative domains of the splicing proteins RNP B1 and RNP B2 is now of interest to rheumatologists. Subjects and methods. The authors studied the frequency of anti-RNP B1 AAbs in 300 patients with systemic ARDs, including those with rheumatoid arthritis (RA), ankylosing spondylitis (AS), systemic lupus erythematosus (SLE), systemic sclerosis (SSc), and Sjö gren's syndrome (SS) and in 53 people without ARDs, who constituted a control group. Serum anti-RNP B1 AAbs were assessed by enzyme immunoassay. Results and discussion. The frequency of anti-RNP B1 AAbs in patients with ARDs was much higher than that in the control group: 170/300 (56.6%) and 8/53 (13%) patients, respectively. Anti-RNP B1 AAbs were detected in 78.5% (113/144) of the patients with RA; 40.3% (23/57) of those with AS, in 67.5% (27/40) of those with SSc, in 36.4% (16/44) of those with SLE, and in 13.3% (2/15) of those with SS. The diagnostic sensitivity of the marker for RA was 78.5%, its diagnostic specificity was 84.9%; the likelihood ratio of positive and negative results was 5.24 and 0.24, respectively. In the patients with RA, the level of anti-RNP B1 AAbs significantly correlated with that of C-reactive protein and erythrocyte sedimentation rate, while in those with SSc the detection of anti-RNP B1 AAbs was related to the rigidity of the vascular wall and the presence of hypertension. The frequency of anti-RNP B1 AAbs among the RA patients seronegative for rheumatoid factor and anti-cyclic citrullinated peptide antibodies was 15.4%. Conclusion. Anti-RNP B1 AAs are a useful laboratory marker (with the upper limit of the normal range being 3.3 U/ml), but are of limited value in the diagnosis of RA. Anti-RNP B1 AAbs may be regarded as an additional diagnostic marker for RA.
format Article
id doaj-art-0b822b33cfe8467e938d4c5d4b4f2cd0
institution Matheson Library
issn 1995-4484
1995-4492
language Russian
publishDate 2017-04-01
publisher IMA PRESS LLC
record_format Article
series Научно-практическая ревматология
spelling doaj-art-0b822b33cfe8467e938d4c5d4b4f2cd02025-08-04T17:03:57ZrusIMA PRESS LLCНаучно-практическая ревматология1995-44841995-44922017-04-0155215916310.14412/1995-4484-2017-159-1632214ANTI-HETEROGENEOUS NUCLEAR RIBONUCLEOPROTEIN B1 (ANTI-RA33) ANTIBODIES IN RHEUMATOID ARTHRITIS AND SYSTEMIC SCLEROSISP. A. Kuznetsova0A. L. Maslyansky1S. V. Lapin2O. Yu. Tkachenko3V. I. Mazurov4V.A. Almazov NorthWestern Federal Medical Research Center, Ministry of Health of Russia, Saint PetersburgV.A. Almazov NorthWestern Federal Medical Research Center, Ministry of Health of Russia, Saint PetersburgAcademician I.P. Pavlov First Saint Petersburg State Medical University, Ministry of Health of Russia, Saint PetersburgAcademician I.P. Pavlov First Saint Petersburg State Medical University, Ministry of Health of Russia, Saint PetersburgI.I. Mechnikov NorthWestern State Medical University, Ministry of Health of Russia, Saint PetersburgAnti-heterogeneous nuclear ribonucleoprotein (RNP) autoantibodies (AAbs) are encountered in many autoimmune rheumatic diseases (ARDs). The potential diagnostic value of the RA33 AAb complex consisting of RNP A2 and alternative domains of the splicing proteins RNP B1 and RNP B2 is now of interest to rheumatologists. Subjects and methods. The authors studied the frequency of anti-RNP B1 AAbs in 300 patients with systemic ARDs, including those with rheumatoid arthritis (RA), ankylosing spondylitis (AS), systemic lupus erythematosus (SLE), systemic sclerosis (SSc), and Sjö gren's syndrome (SS) and in 53 people without ARDs, who constituted a control group. Serum anti-RNP B1 AAbs were assessed by enzyme immunoassay. Results and discussion. The frequency of anti-RNP B1 AAbs in patients with ARDs was much higher than that in the control group: 170/300 (56.6%) and 8/53 (13%) patients, respectively. Anti-RNP B1 AAbs were detected in 78.5% (113/144) of the patients with RA; 40.3% (23/57) of those with AS, in 67.5% (27/40) of those with SSc, in 36.4% (16/44) of those with SLE, and in 13.3% (2/15) of those with SS. The diagnostic sensitivity of the marker for RA was 78.5%, its diagnostic specificity was 84.9%; the likelihood ratio of positive and negative results was 5.24 and 0.24, respectively. In the patients with RA, the level of anti-RNP B1 AAbs significantly correlated with that of C-reactive protein and erythrocyte sedimentation rate, while in those with SSc the detection of anti-RNP B1 AAbs was related to the rigidity of the vascular wall and the presence of hypertension. The frequency of anti-RNP B1 AAbs among the RA patients seronegative for rheumatoid factor and anti-cyclic citrullinated peptide antibodies was 15.4%. Conclusion. Anti-RNP B1 AAs are a useful laboratory marker (with the upper limit of the normal range being 3.3 U/ml), but are of limited value in the diagnosis of RA. Anti-RNP B1 AAbs may be regarded as an additional diagnostic marker for RA.https://rsp.mediar-press.net/rsp/article/view/2357ra33anti-rnp b1 autoantibodiessystemic sclerosisrheumatoid arthritis
spellingShingle P. A. Kuznetsova
A. L. Maslyansky
S. V. Lapin
O. Yu. Tkachenko
V. I. Mazurov
ANTI-HETEROGENEOUS NUCLEAR RIBONUCLEOPROTEIN B1 (ANTI-RA33) ANTIBODIES IN RHEUMATOID ARTHRITIS AND SYSTEMIC SCLEROSIS
Научно-практическая ревматология
ra33
anti-rnp b1 autoantibodies
systemic sclerosis
rheumatoid arthritis
title ANTI-HETEROGENEOUS NUCLEAR RIBONUCLEOPROTEIN B1 (ANTI-RA33) ANTIBODIES IN RHEUMATOID ARTHRITIS AND SYSTEMIC SCLEROSIS
title_full ANTI-HETEROGENEOUS NUCLEAR RIBONUCLEOPROTEIN B1 (ANTI-RA33) ANTIBODIES IN RHEUMATOID ARTHRITIS AND SYSTEMIC SCLEROSIS
title_fullStr ANTI-HETEROGENEOUS NUCLEAR RIBONUCLEOPROTEIN B1 (ANTI-RA33) ANTIBODIES IN RHEUMATOID ARTHRITIS AND SYSTEMIC SCLEROSIS
title_full_unstemmed ANTI-HETEROGENEOUS NUCLEAR RIBONUCLEOPROTEIN B1 (ANTI-RA33) ANTIBODIES IN RHEUMATOID ARTHRITIS AND SYSTEMIC SCLEROSIS
title_short ANTI-HETEROGENEOUS NUCLEAR RIBONUCLEOPROTEIN B1 (ANTI-RA33) ANTIBODIES IN RHEUMATOID ARTHRITIS AND SYSTEMIC SCLEROSIS
title_sort anti heterogeneous nuclear ribonucleoprotein b1 anti ra33 antibodies in rheumatoid arthritis and systemic sclerosis
topic ra33
anti-rnp b1 autoantibodies
systemic sclerosis
rheumatoid arthritis
url https://rsp.mediar-press.net/rsp/article/view/2357
work_keys_str_mv AT pakuznetsova antiheterogeneousnuclearribonucleoproteinb1antira33antibodiesinrheumatoidarthritisandsystemicsclerosis
AT almaslyansky antiheterogeneousnuclearribonucleoproteinb1antira33antibodiesinrheumatoidarthritisandsystemicsclerosis
AT svlapin antiheterogeneousnuclearribonucleoproteinb1antira33antibodiesinrheumatoidarthritisandsystemicsclerosis
AT oyutkachenko antiheterogeneousnuclearribonucleoproteinb1antira33antibodiesinrheumatoidarthritisandsystemicsclerosis
AT vimazurov antiheterogeneousnuclearribonucleoproteinb1antira33antibodiesinrheumatoidarthritisandsystemicsclerosis